PharmaShots | Incisive News in 3 Shots

Subscribe Now

lumacaftor

Vertex Receives EC’s Approval for the Label Extension of Orkambi to Treat Children with Cystic Fibrosis Aged 1 to <2 Years

Vertex Receives EC’s Approval for the Label Extension of Orkambi to Treat Children with Cystic Fibrosis Aged 1 to <2 Years

July 5, 2023

Vertex’s Orkambi (lumacaftor/ivacaftor) Receives EMA’s CHMP Positive Opinion for Children With Cystic Fibrosis Ages 1 to <2 Years

Vertex’s Orkambi (lumacaftor/ivacaftor) Receives EMA’s CHMP Positive Opinion for Children With Cystic Fibrosis Ages 1 to <2 Years

April 27, 2023

Vertex’s Orkambi (lumacaftor/ivacaftor) Receives Health Canada’s Market Authorization for Children with Cystic Fibrosis Aged 1 to <2 Years

Vertex’s Orkambi (lumacaftor/ivacaftor) Receives Health Canada’s Market Authorization for Children with Cystic Fibrosis Aged 1 to...

April 11, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us